市場調査レポート

商品コード

1466419

希少疾患遺伝子検査市場：疾患タイプ、技術、専門分野、エンドユーザー別-世界予測2024-2030年

Rare Disease Genetic Testing Market by Disease Type (Cancer, Cardiovascular Disorders, Dermatology Diseases), Technology (Array Technology, FISH, Karyotyping), Specialty, End-User - Global Forecast 2024-2030

出版日: 2024年04月17日 | 発行: 360iResearch

| ページ情報: 英文 181 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF, Excel & Online Access - 1 Year (Single User License)

USD 4,749 746,257円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Up to 5 User License)

USD 5,749 903,397円

レポートPDF及びExcelを5名まで共有ご利用頂けるライセンスです。ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Site License)

USD 6,749 1,060,537円

レポートPDF及びExcelを同一事業所（所在地）内のすべての方でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Enterprise User License)

USD 8,749 1,374,817円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

希少疾患遺伝子検査市場規模は2023年に13億3,000万米ドルと推定され、2024年には15億4,000万米ドルに達し、CAGR 16.15％で2030年には38億米ドルに達すると予測されています。

希少疾患遺伝子検査とは、DNA、RNA、染色体、タンパク質、特定の代謝産物を分析し、希少疾患につながる可能性のある遺伝子変異や異常を特定するプロセスを指します。希少疾患の多くは遺伝的なものであるため、このような検査は早期かつ正確な診断のために極めて重要です。ゲノム技術の進歩は、遺伝子検査のコストを大幅に削減し、スピードと精度を向上させています。さらに、希少疾患の管理における早期かつ正確な診断の重要性に対する認識と理解が高まり、こうした検査に対する需要が増加しています。しかし、不確かであいまいな結果が出る可能性やプライバシーに関する問題、遺伝的差別の可能性は、遺伝子検査の有用性に影響を与えます。これらの問題に対処するためには、遺伝子検査のプライバシーと倫理的行為を保証するための厳格なガイドラインと規制が施行されなければならないです。継続的な科学の進歩に伴い、次世代シーケンシングのような、より洗練された包括的な検査方法の開発が目前に迫っています。さらに、消費者主導型ヘルスケアへの動向も高まっており、消費者直販型の遺伝子検査キット市場が強化される可能性があります。

主な市場の統計
基準年［2023]	13億3,000万米ドル
予測年［2024]	15億4,000万米ドル
予測年 [2030]	38億米ドル
CAGR（%）	16.15%

疾患の種類希少遺伝性疾患のスクリーニングニーズに対応する高度検査の開発

希少がんの遺伝子検査は、腫瘍形成を促進する遺伝性変異や体細胞変異を特定することができます。このような検査は、標的療法に情報を与えることができるため、個別化医療アプローチにとって極めて重要です。心血管系疾患の遺伝子検査は、心筋症や不整脈などの疾患の原因となる変異を突き止めることができ、患者管理や家族スクリーニングに重要な意味を持っています。表皮水疱症などの希少な遺伝性皮膚疾患は、管理および遺伝子治療の可能性に役立つ遺伝子診断検査の焦点となっています。先天性副腎過形成やフェニルケトン尿症などの疾患は、診断を確定し、食事療法や医学的介入を可能にするために遺伝子検査が必要です。希少な血液疾患、すなわち血友病や鎌状赤血球症の遺伝子検査は、治療法の決定、予後、遺伝カウンセリングのために有用です。原発性免疫不全症などの免疫学的疾患では、遺伝子検査によって特異的な免疫機能異常を判定し、適切な治療を導くことができます。デュシェンヌ型筋ジストロフィーを含む筋骨格系に影響を及ぼす希少遺伝性疾患は、早期介入や遺伝カウンセリングのための遺伝子検査が有益です。ハンチントン病や様々な運動失調症などの疾患の遺伝子検査は、予後、対症療法計画、生殖の決定に不可欠です。

エンドユーザー：学術機関の研究室における希少遺伝子検査に関する新たな調査

診断検査室は、遺伝子解析を実施する主要な場として、希少疾患遺伝子検査市場において極めて重要な役割を果たしています。診断検査施設は、正確な診断と治療計画の立案に不可欠な包括的遺伝子検査サービスを提供する専門知識を有していることから、ニーズに基づく選好が生じる。これらの検査施設は、シークエンシングから遺伝子パネルまで、幅広い遺伝子アッセイを実施できる高度な技術を備えています。病院や診療所も希少疾患遺伝子検査の重要なエンドユーザーであり、患者に直接ケアや診断を提供しています。これらの環境では、患者管理とシームレスに統合され、ケアへの集学的アプローチを可能にする遺伝子検査サービスが優先されます。研究機関やCRO（医薬品開発業務受託機関）は、希少疾患遺伝子検査を好む特殊なエンドユーザーであり、研究イニシアティブや医薬品開発をサポートする必要性に駆られています。このような環境では、病気の病態を理解し、バイオマーカーを同定し、臨床試験を進めるために遺伝子検査が使用されます。

地域別インサイト

南北アメリカは、堅牢な遺伝子検査インフラとヘルスケアプロバイダーや患者の高い認識レベルを示しており、大手企業の強力なプレゼンスと支持的な規制枠組みによって支えられています。希少疾患研究に対する調査と投資は、遺伝子検査の普及と生産に寄与しています。APAC地域は急成長しているが、希少疾患遺伝子検査へのアクセスや採用には格差があります。日本とオーストラリアは、技術の進歩と政府支援の増加でリードしています。この地域では、世界企業とのコラボレーションが生産と使用を形成しており、研究開発に投資する地元企業も増えています。一方、EMEA（欧州・中東・アフリカ）地域は多様な様相を呈しています。西欧は、技術導入と生産能力において南北アメリカを反映しており、老舗企業が成長を牽引しています。GDPRを含むEUの規制は遺伝子データ利用に影響を与え、市場にプラスとマイナスの両方の影響を与えます。中東とアフリカは、認知度が徐々に高まりつつある新興市場です。これらの地域での遺伝子検査は散発的に利用されており、主に国際的な援助やパートナーシップによって促進されています。この地域の企業は、大手の多国籍診断会社から希少疾患の遺伝学に特化した専門バイオテクノロジー企業まで多岐にわたる。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは希少疾患遺伝子検査市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、希少疾患遺伝子検査市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.希少疾患遺伝子検査市場の市場規模および予測は？

2.希少疾患遺伝子検査市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.希少疾患遺伝子検査市場の技術動向と規制枠組みは？

4.希少疾患遺伝子検査市場における主要ベンダーの市場シェアは？

5.希少疾患遺伝子検査市場への参入に適した形態や戦略的手段は？

市場力学
- 促進要因
  - 希少遺伝性疾患の蔓延と早期かつ迅速な診断の必要性
  - 新たな変異の特定のためのトランスレーショナル研究およびゲノム調査における利用の増加
  - 希少疾患の診断と治療に関する政府の取り組み
- 抑制要因
  - 希少疾患に関する倫理的懸念と限られた情報へのアクセス
- 機会
  - 新たな希少疾患遺伝子を特定するための遺伝子技術の進歩
  - 希少遺伝性疾患の診断に対する有利な投資
- 課題
  - 新たな希少疾患遺伝子検査の承認プロセスに関連する厳格な規制
市場セグメンテーション分析
- 疾患タイプ：希少遺伝性疾患のスクリーニングニーズに応える高度な検査の開発
- エンドユーザー：学術機関の調査室における希少遺伝子検査に関する新たな研究
市場動向分析
ロシア・ウクライナ紛争の累積的影響
高インフレの累積的影響
ポーターのファイブフォース分析
バリューチェーンとクリティカルパス分析
規制枠組みの分析
顧客のカスタマイズ

第6章希少疾患遺伝子検査市場：疾患タイプ別

がん
心血管疾患
皮膚科疾患
内分泌・代謝疾患
血液疾患
免疫疾患
筋骨格障害
神経学的障害

第7章希少疾患遺伝子検査市場：技術別

アレイテクノロジー
魚
核型分析
次世代シーケンシング
PCRベースの検査
サンガーシーケンス

第8章希少疾患遺伝子検査市場専門分野別

生化学的遺伝子検査
染色体遺伝子検査
分子遺伝学的検査

第9章希少疾患遺伝子検査市場：エンドユーザー別

診断検査室
病院・クリニック
調査機関とCRO

第10章南北アメリカの希少疾患遺伝子検査市場

アルゼンチン
ブラジル
カナダ
メキシコ
米国

第11章アジア太平洋地域の希少疾患遺伝子検査市場

オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第12章欧州・中東・アフリカの希少疾患遺伝子検査市場

デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第13章競合情勢

市場シェア分析2023
FPNVポジショニングマトリックス、2023
競合シナリオ分析
- Burjeel Holdings、米国のBridgebio Pharmaと提携し希少疾患研究開発プロジェクト「Nader」を開始
- NIH、正常なヒト細胞と組織における遺伝的変異の調査に1億4,000万米ドルの取り組みを開始
- CENTOGENE、希少疾患および神経変性疾患の診断のための全ゲノムシーケンスソリューション、新しいCentoGenomeを発表

第14章競合ポートフォリオ

主要企業プロファイル
主要製品ポートフォリオ

図表

LIST OF FIGURES

FIGURE 1. RARE DISEASE GENETIC TESTING MARKET RESEARCH PROCESS
FIGURE 2. RARE DISEASE GENETIC TESTING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. RARE DISEASE GENETIC TESTING MARKET DYNAMICS
FIGURE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2030 (%)
FIGURE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

TABLE 1. RARE DISEASE GENETIC TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 55. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 56. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 57. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 58. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 59. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2018-2023 (USD MILLION)
TABLE 60. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2024-2030 (USD MILLION)
TABLE 61. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 62. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 63. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 64. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 65. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 66. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 67. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 68. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 69. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 70. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 71. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 72. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 73. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 74. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 75. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 76. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 77. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 78. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 79. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 80. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 81. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 82. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 83. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 84. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 85. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 86. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 87. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 88. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 89. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 90. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 91. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 92. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 93. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 94. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 95. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 96. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 97. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 98. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 99. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 100. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 101. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 102. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 103. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 104. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 105. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 106. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 107. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 108. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 109. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 110. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 111. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 112. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 113. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 114. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 115. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 116. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 117. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 118. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 119. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 120. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 121. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 122. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 123. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 124. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 126. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 128. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 130. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 132. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 134. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 136. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 137. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 138. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 139. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 140. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 141. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 142. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 143. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 144. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 145. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 146. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 147. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 148. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 149. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 150. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 151. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 152. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 153. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 154. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 155. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 156. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 157. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 158. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 159. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 160. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 161. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 162. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 163. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 164. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 165. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 166. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 167. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 168. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 169. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 170. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 171. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 172. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 173. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 174. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 175. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 176. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 177. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 178. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 179. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 180. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 181. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 182. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 183. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 184. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 185. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 186. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 187. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 188. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 189. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 190. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 191. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 192. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 193. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 194. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 195. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 196. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 197. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 198. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 199. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 200. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 201. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 202. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 203. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 204. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 205. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 206. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 207. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 208. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 209. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 210. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 211. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 212. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 213. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 214. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 215. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 216. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 217. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 218. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 219. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 220. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 221. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 222. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 223. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 224. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 225. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 226. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 227. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 228. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 229. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 230. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 231. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 232. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 233. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 234. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 235. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 236. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 237. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 238. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 239. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 240. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 241. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 242. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 243. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 244. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 245. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 246. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 247. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 248. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 249. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 250. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 251. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 252. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 253. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 254. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 255. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 256. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 269. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 270. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 271. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 272. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 273. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 274. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 275. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 276. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 277. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 278. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 279. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 280. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 281. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 282. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 283. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 284. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 285. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 286. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 287. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 288. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 289. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 290. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 291. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 292. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 293. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 294. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 295. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 296. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 297. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 298. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 299. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 300. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 301. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 302. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 303. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
TABLE 304. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
TABLE 305. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
TABLE 306. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
TABLE 307. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 308. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 309. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 310. GERMANY RARE D

Product Code: MRR-B9334AD6C623

[181 Pages Report] The Rare Disease Genetic Testing Market size was estimated at USD 1.33 billion in 2023 and expected to reach USD 1.54 billion in 2024, at a CAGR 16.15% to reach USD 3.80 billion by 2030.

Rare disease genetic testing refers to the process of analyzing DNA, RNA, chromosomes, proteins, or certain metabolites to identify genetic mutations or abnormalities that may lead to a rare disease. Since rare diseases are predominantly genetic in origin, such tests are pivotal for early and accurate diagnosis. Advances in genomic technologies have significantly reduced the cost and increased the speed and accuracy of genetic tests. Moreover, there is a growing awareness and understanding of the importance of early and precise diagnosis in managing rare diseases, which has led to a rise in demand for these tests. However, the possibility of uncertain or ambiguous results and issues related to privacy, and the potential for genetic discrimination impact the utility of genetic testing. To address these issues, stringent guidelines and regulations must be enforced to ensure the privacy and ethical conduct of genetic testing. With ongoing scientific advancements, the development of more sophisticated and comprehensive testing methods, such as next-generation sequencing, is on the horizon. Additionally, there is an increasing trend toward consumer-driven healthcare, which may bolster the market for direct-to-consumer genetic testing kits.

KEY MARKET STATISTICS
Base Year [2023]	USD 1.33 billion
Estimated Year [2024]	USD 1.54 billion
Forecast Year [2030]	USD 3.80 billion
CAGR (%)	16.15%

Disease Type: Development of advanced tests to cater to the screening needs of rare genetic diseases

Genetic tests for rare cancers can identify hereditary or somatic mutations that drive tumorigenesis. Such tests are critical for personalized medicine approaches, as they can inform targeted therapies. Genetic testing for cardiovascular disorders can pinpoint mutations that contribute to conditions such as cardiomyopathies and arrhythmias, which have significant implications for patient management and family screening. Rare genetic skin diseases, such as epidermolysis bullosa, have been the focus of genetic diagnostic tests to help with management and potential gene therapy. Conditions such as congenital adrenal hyperplasia and phenylketonuria require genetic testing to confirm diagnoses and enable dietary and medical interventions. Genetic tests for rare hematological conditions, namely hemophilia and sickle cell disease, are valuable for treatment decisions, prognosis, and genetic counseling. Immunological disorders such as primary immunodeficiencies where genetic testing can determine specific immune dysfunctions to guide appropriate treatments. Rare genetic disorders affecting the musculoskeletal system, including Duchenne Muscular Dystrophy, benefit from genetic testing for early intervention and genetic counseling. Genetic tests for disorders such as Huntington's disease and various ataxias are essential for prognosis, symptomatic treatment plans, and reproductive decisions.

End-User: Emerging studies on rare genetic testing in research laboratories in academic institutes

Diagnostic laboratories play a pivotal role in the rare disease genetic testing market as a primary setting for conducting genetic analyses. The need-based preference for diagnostic laboratories arises from their expertise in providing comprehensive genetic testing services, which are essential for accurate diagnosis and guiding treatment plans. These laboratories are well-equipped with advanced technologies capable of performing a wide array of genetic assays, from sequencing to gene panels. Hospitals and clinics represent another critical end-user of rare disease genetic testing, offering direct patient care and diagnosis. These settings prioritize genetic testing services that integrate seamlessly with patient management and allow for multidisciplinary approaches to care. Research laboratories and contract research organizations (CROs) are specialized end-users whose preference for rare disease genetic testing is driven by the need to support research initiatives or drug development. These settings use genetic testing for understanding disease pathology, identifying biomarkers, and advancing clinical trials.

Regional Insights

The Americas exhibit a robust genetic testing infrastructure and a high awareness level among healthcare providers and patients, bolstered by a strong presence of leading companies and supportive regulatory frameworks. Reimbursement policies and investments in rare disease research contribute to the widespread use and production of genetic tests. The APAC region, while rapidly growing, reveals disparities in access and adoption of rare disease genetic testing. Japan and Australia lead with advancements in technology and increasing government support. Collaborations with global entities shape the production and use in this region, and a growing number of local players are investing in R&D. Meanwhile, the EMEA region presents a diverse landscape; Western Europe mirrors the Americas in terms of technology adoption and production capabilities, with well-established companies driving growth. The EU's regulations, including GDPR, impact genetic data usage, having both positive and negative implications on the market. The Middle East and Africa are nascent markets where awareness is gradually increasing. Genetic testing in these areas is sporadically utilized, primarily facilitated by international aid and partnerships. Companies range from large multinational diagnostics firms to specialized biotechs focused on rare disease genetics in this region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Rare Disease Genetic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Rare Disease Genetic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Rare Disease Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include 3billion, Inc., Ambry Genetics Corporation, Arup Laboratories, Baylor Genetics, Biora Therapeutics, Inc., Blueprint Genetics Oy, Caris Life Sciences, Centogene N.V., Color Health, Inc., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., GeneDx, LLC, Genomelink, Inc., Helix OpCo, LLC, Illumina, Inc., Integrated DNA Technologies, Inc. by Danaher Corporation, Invitae Corporation, Laboratory Corporation Of America Holdings, Macrogen, Inc., Myriad Genetics, Inc., Nonacus Limited, OPKO Health, Inc., PerkinElmer Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Realm IDX, Inc., Sanofi S.A., The Cooper Companies, Inc., Thermo Fisher Scientific Inc., and Variantyx, Inc..

Market Segmentation & Coverage

This research report categorizes the Rare Disease Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Disease Type
- Cancer
- Cardiovascular Disorders
- Dermatology Diseases
- Endocrine & Metabolism Diseases
- Hematology Diseases
- Immunological Disorders
- Musculoskeletal Disorders
- Neurological Disorders

Technology
- Array Technology
- FISH
- Karyotyping
- Next Generation Sequencing
  - Whole Exome Sequencing
  - Whole Genome Sequencing

PCR - Based Testing
Sanger Sequencing

Specialty
- Biochemical Genetic Tests
- Chromosomal Genetic Tests
- Molecular Genetic Tests

End-User
- Diagnostic Laboratories
- Hospitals & Clinics
- Research Laboratories & CROs

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Rare Disease Genetic Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Rare Disease Genetic Testing Market?

3. What are the technology trends and regulatory frameworks in the Rare Disease Genetic Testing Market?

4. What is the market share of the leading vendors in the Rare Disease Genetic Testing Market?

5. Which modes and strategic moves are suitable for entering the Rare Disease Genetic Testing Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
  - 5.1.1.2. Rising Use in Translational & Genomic Research for Identification of Novel Mutations
  - 5.1.1.3. Government Initiatives for Diagnosis and Treatment of Rare Diseases
- 5.1.2. Restraints
  - 5.1.2.1. Ethical Concerns and Access to Limited Information on Rare Disease
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in Genetic Technology to Identify New Rare Disease Genes
  - 5.1.3.2. Favorable Investments for Diagnosis of Rare Genetic Diseases
- 5.1.4. Challenges
  - 5.1.4.1. Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test
5.2. Market Segmentation Analysis
- 5.2.1. Disease Type: Development of advanced tests to cater to the screening needs of rare genetic diseases
- 5.2.2. End-User: Emerging studies on rare genetic testing in research laboratories in academic institutes
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Rare Disease Genetic Testing Market, by Disease Type

6.1. Introduction
6.2. Cancer
6.3. Cardiovascular Disorders
6.4. Dermatology Diseases
6.5. Endocrine & Metabolism Diseases
6.6. Hematology Diseases
6.7. Immunological Disorders
6.8. Musculoskeletal Disorders
6.9. Neurological Disorders

7. Rare Disease Genetic Testing Market, by Technology

7.1. Introduction
7.2. Array Technology
7.3. FISH
7.4. Karyotyping
7.5. Next Generation Sequencing
7.6. PCR - Based Testing
7.7. Sanger Sequencing

8. Rare Disease Genetic Testing Market, by Specialty

8.1. Introduction
8.2. Biochemical Genetic Tests
8.3. Chromosomal Genetic Tests
8.4. Molecular Genetic Tests

9. Rare Disease Genetic Testing Market, by End-User

9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals & Clinics
9.4. Research Laboratories & CROs

10. Americas Rare Disease Genetic Testing Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Rare Disease Genetic Testing Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Rare Disease Genetic Testing Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Burjeel Holdings To Launch Rare Disease Research & Development Project 'Nader' In Partnership With US-Based Bridgebio Pharma
- 13.3.2. NIH Launches USD 140 Million Effort To Investigate Genetic Variation In Normal Human Cells And Tissues
- 13.3.3. CENTOGENE Launches NEW CentoGenome, A Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio

希少疾患遺伝子検査市場：疾患タイプ、技術、専門分野、エンドユーザー別-世界予測2024-2030年

Rare Disease Genetic Testing Market by Disease Type (Cancer, Cardiovascular Disorders, Dermatology Diseases), Technology (Array Technology, FISH, Karyotyping), Specialty, End-User - Global Forecast 2024-2030

本レポートは、以下の側面に関する貴重な洞察を提供しています：

本レポートは、以下のような主要な質問に対応しています：

目次

第1章序文

第2章調査手法

第3章エグゼクティブサマリー

第4章市場の概要

第5章市場洞察

第6章希少疾患遺伝子検査市場：疾患タイプ別

第7章希少疾患遺伝子検査市場：技術別

第8章希少疾患遺伝子検査市場専門分野別

第9章希少疾患遺伝子検査市場：エンドユーザー別

第10章南北アメリカの希少疾患遺伝子検査市場

第11章アジア太平洋地域の希少疾患遺伝子検査市場

第12章欧州・中東・アフリカの希少疾患遺伝子検査市場

第13章競合情勢

第14章競合ポートフォリオ

LIST OF FIGURES

LIST OF TABLES

This research report categorizes the Rare Disease Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Rare Disease Genetic Testing Market, by Disease Type

7. Rare Disease Genetic Testing Market, by Technology

8. Rare Disease Genetic Testing Market, by Specialty

9. Rare Disease Genetic Testing Market, by End-User

10. Americas Rare Disease Genetic Testing Market

11. Asia-Pacific Rare Disease Genetic Testing Market

12. Europe, Middle East & Africa Rare Disease Genetic Testing Market

13. Competitive Landscape

14. Competitive Portfolio

希少疾患遺伝子検査市場：疾患タイプ、技術、専門分野、エンドユーザー別-世界予測2024-2030年

Rare Disease Genetic Testing Market by Disease Type (Cancer, Cardiovascular Disorders, Dermatology Diseases), Technology (Array Technology, FISH, Karyotyping), Specialty, End-User - Global Forecast 2024-2030

本レポートは、以下の側面に関する貴重な洞察を提供しています：

本レポートは、以下のような主要な質問に対応しています：

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 希少疾患遺伝子検査市場：疾患タイプ別

第7章 希少疾患遺伝子検査市場：技術別

第8章 希少疾患遺伝子検査市場専門分野別

第9章 希少疾患遺伝子検査市場：エンドユーザー別

第10章 南北アメリカの希少疾患遺伝子検査市場

第11章 アジア太平洋地域の希少疾患遺伝子検査市場

第12章 欧州・中東・アフリカの希少疾患遺伝子検査市場

第13章 競合情勢

第14章 競合ポートフォリオ

LIST OF FIGURES

LIST OF TABLES

This research report categorizes the Rare Disease Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Rare Disease Genetic Testing Market, by Disease Type

7. Rare Disease Genetic Testing Market, by Technology

8. Rare Disease Genetic Testing Market, by Specialty

9. Rare Disease Genetic Testing Market, by End-User

10. Americas Rare Disease Genetic Testing Market

11. Asia-Pacific Rare Disease Genetic Testing Market

12. Europe, Middle East & Africa Rare Disease Genetic Testing Market

13. Competitive Landscape

14. Competitive Portfolio

第1章序文

第2章調査手法

第3章エグゼクティブサマリー

第4章市場の概要

第5章市場洞察

第6章希少疾患遺伝子検査市場：疾患タイプ別

第7章希少疾患遺伝子検査市場：技術別

第8章希少疾患遺伝子検査市場専門分野別

第9章希少疾患遺伝子検査市場：エンドユーザー別

第10章南北アメリカの希少疾患遺伝子検査市場

第11章アジア太平洋地域の希少疾患遺伝子検査市場

第12章欧州・中東・アフリカの希少疾患遺伝子検査市場

第13章競合情勢

第14章競合ポートフォリオ